Chinese VC alliance to back early-stage bio-ventures

A variety of public and private venture groups in China have created a loosely structured association that will back early-stage biotech ventures. Companies such as Shijiazhuang Pharmaceutical Group, DSM China and the Chinese Academy of Sciences plan to raise $145 million in the near term. And much of that money will be earmarked for biopharmaceuticals, biomaterials and industrial enzymes.

- read the report from China Bio Today

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.